Source:http://linkedlifedata.com/resource/pubmed/id/11051596
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1-3
|
pubmed:dateCreated |
2000-11-16
|
pubmed:abstractText |
We have evaluated the efficacy of interferon-alpha (IFN-alpha) plus zinc therapy in hepatitis C patients with genotype 1b, poor responders for IFN alone. Ten patients were injected with 10 MU of IFN-alpha every day for 4 wk, followed by three times a week for 20 wk (control group). Nine patients took 300 mg of zinc sulfate a day orally during IFN-alpha therapy (zinc sulfate group), and 15 patients took IFN-alpha and 150 mg of polaprezinc (polaprezinc group). On the d 8 of IFN therapy, circadian zinc levels in serum elevated significantly in the polaprezinc group compared to the zinc sulfate group or control group. Serum ALT levels normalized in 73.3% of the polaprezinc group, 55.6% of the zinc sulfate group, and 40.0% of the control group at 6 mo after the end of IFN therapy. Sustained eradication for the hepatitis C virus RNA judged at the end of the 6-mo follow-up period was higher in the polaprezinc group than in the zinc sulfate group (53.3% vs 11.1%, p < 0.05) or the control group (20.0%). No clinical side effects of zinc were observed at the dose used. The data suggest that polaprezinc is expected to increase the therapeutic response of IFN-alpha for chronic hepatitis C with genotype 1b.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Carnosine,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Organometallic Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Porphobilinogen Synthase,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Zinc,
http://linkedlifedata.com/resource/pubmed/chemical/Zinc Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Zinc Sulfate,
http://linkedlifedata.com/resource/pubmed/chemical/polaprezinc
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0163-4984
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
75
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
53-63
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11051596-Carnosine,
pubmed-meshheading:11051596-Circadian Rhythm,
pubmed-meshheading:11051596-Drug Therapy, Combination,
pubmed-meshheading:11051596-Female,
pubmed-meshheading:11051596-Genotype,
pubmed-meshheading:11051596-Hepatitis C, Chronic,
pubmed-meshheading:11051596-Humans,
pubmed-meshheading:11051596-Interferon-alpha,
pubmed-meshheading:11051596-Male,
pubmed-meshheading:11051596-Middle Aged,
pubmed-meshheading:11051596-Organometallic Compounds,
pubmed-meshheading:11051596-Porphobilinogen Synthase,
pubmed-meshheading:11051596-RNA, Viral,
pubmed-meshheading:11051596-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:11051596-Zinc,
pubmed-meshheading:11051596-Zinc Compounds,
pubmed-meshheading:11051596-Zinc Sulfate
|
pubmed:year |
2000
|
pubmed:articleTitle |
Preliminary study of combination therapy with interferon-alpha and zinc in chronic hepatitis C patients with genotype 1b.
|
pubmed:affiliation |
Department of Health Science, Gunma University School of Medicine, Maebashi, Japan.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Controlled Clinical Trial
|